<p>Cytotoxicity of a series of nicotinonitrile-based derivatives with the molecular target and apoptosis activity against PC-3 cells was described. Compound <b>7b</b> exhibited remarkable cytotoxicity against MCF-7 and PC-3 cells with IC<sub>50</sub> values of 3.58 μM and 3.60 μM, respectively. Interestingly, compounds <b>4k</b> and <b>7b</b> had potent PIM-1 kinase inhibition with IC<sub>50</sub> values of 21.2 nM and 18.9 nM, respectively, with inhibition of 92.7 and 96.4% compared to Staurosporine (IC<sub>50</sub> = 16.7 nM, with 95.6% inhibition). Moreover, compound <b>7b</b> significantly activated apoptosis in PC-3 cells, increasing the apoptotic cell death, increasing total apoptosis by 34.21% compared to 0.9% in control cells, and arresting the cell cycle at the G1 pahse. In vivo model of SEC-bearing mice confirmed the anticancer activity of compound <b>7b</b> by having 42.9% compared to the 5-FU treatment of 54.2%; it maintained the physiological activity of hematological and biochemical parameters. Molecular docking effectively sheds insight into the mechanism of PIM-1 kinase inhibition by revealing the binding interactions between the lead chemical <b>7b</b> and the PIM-1 protein. The results showed that compound <b>7b</b> showed promise as a chemotherapeutic drug targeting PIM-1 for the treatment of breast cancer.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Anticancer potential of nicotinonitrile derivatives as PIM-1 kinase inhibitors through apoptosis: in vitro and in vivo studies

  • Sara Salem Ali,
  • Mohamed S. Nafie,
  • Hanan A. Farag,
  • Atef M. Amer

摘要

Cytotoxicity of a series of nicotinonitrile-based derivatives with the molecular target and apoptosis activity against PC-3 cells was described. Compound 7b exhibited remarkable cytotoxicity against MCF-7 and PC-3 cells with IC50 values of 3.58 μM and 3.60 μM, respectively. Interestingly, compounds 4k and 7b had potent PIM-1 kinase inhibition with IC50 values of 21.2 nM and 18.9 nM, respectively, with inhibition of 92.7 and 96.4% compared to Staurosporine (IC50 = 16.7 nM, with 95.6% inhibition). Moreover, compound 7b significantly activated apoptosis in PC-3 cells, increasing the apoptotic cell death, increasing total apoptosis by 34.21% compared to 0.9% in control cells, and arresting the cell cycle at the G1 pahse. In vivo model of SEC-bearing mice confirmed the anticancer activity of compound 7b by having 42.9% compared to the 5-FU treatment of 54.2%; it maintained the physiological activity of hematological and biochemical parameters. Molecular docking effectively sheds insight into the mechanism of PIM-1 kinase inhibition by revealing the binding interactions between the lead chemical 7b and the PIM-1 protein. The results showed that compound 7b showed promise as a chemotherapeutic drug targeting PIM-1 for the treatment of breast cancer.